Phenotype and functionality of the infusion products | Clinical outcome | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Patient number | Infused cells | CD8+ | CD45RO+ | CCR7+ | CD27+ | Reactivitya | Total number of responding CD8+ T cells infused | Response | TTP | OS |
(x 1010) | (%) | (%) | (%) | (% of CD8) | (%) | (x 106) | (RECIST) | (mo) | (mo) | |
1 | 2.9 | 94 | 99.7 | 7.5 | 6.1 | 28.8 # | 6460 | CR | 30+ | 30+ |
2 | 1.8 | 92 | 97.4 | 4.9 | 5.2 | 1.0# | 175 | PD | 2 | 7 |
3 | 2.0 | 95 | 99.4 | 6.1 | 0.5 | 0.0# | 7 | SD | 4 | 11.5 |
6 | 0.3 | 47 | 98.4 | 3.9 | 1.2 | 0.9* | 41 | PD | 2 | 4.6 |
7 | 1.3 | 88 | 89 | 31.8 | 3.4 | 0.4# | 44 | SD | 5 | 11 |
11 | 7.5 | 95 | 99 | 0.6 | 8.1 | 6.0* | 4377 | CR | 10+ | 10+ |